The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.

Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA (sa-mRNA) vaccine candidate, ARCT-2304, for active immunization to ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

Meanwhile Arcturus, a San Diego biotech working with messenger RNA (mRNA) therapies said it is working with Duke-NUS Medical School (Duke-NUS) to develop a coronavirus vaccine for Singapore.

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive is the first in the new sa-mRNA class to be approved for marketing in the EU. The importance of biosimilars only continues to grow ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

To do that, find Arcturus, the brightest star breaking over the horizon, around 8:30 p.m. and look right below it, he added. But don’t fixate on that point, though. “Kind of relax your eyes and just ...

Who’s at the peak? COVID-19 has hit some countries far harder than others, though differences in the way infections are counted locally make it impossible to make a perfect apples-to-apples ...

Japanese version The data on this "Coronavirus (COVID-19) infections in Japan" page is based on original coverage by the Mainichi Shimbun and press releases from the Ministry of Health ...